Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily ...
Seles’ first symptoms appeared suddenly around three years ago. She began having double vision and weakness in her arms and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback